UCB, Bio­gen ad­mit de­feat in PhII lu­pus tri­al, adding to a string of late-stage fail­ures in the field

A late-stage lu­pus pro­gram at UCB and Bio­gen has fol­lowed sev­er­al ri­vals in­to a wall.

With­out pro­vid­ing de­tails, the part­ners re­port­ed that their drug, dapirolizum­ab …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.